Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Can we get a reality check on PP405?

      in Research/Science  81 upvotes 8 months ago
      PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

      community VDPHL01 works really quickly .. apparently?

      in Research/Science  48 upvotes 3 months ago
      VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

      community Hi, I got some regrowth recently and I attribute it to DICLOFENAC

      in Research/Science  6 upvotes 2 years ago
      The user started balding at 16/17 and tried various treatments including minoxidil, finasteride, and dutasteride with little success. They recently started applying diclofenac gel to their bald areas and noticed some hair regrowth, attributing this to diclofenac's ability to lower prolactin levels and its anti-inflammatory effects.

      community Is S5 plus cream an okay alternative to finasteride?

      in Finasteride  4 upvotes 9 years ago
      The conversation discusses using S5 plus cream (Spironolactone, Alfatradiol, and Tempol) as an alternative to finasteride for hair loss, with concerns about its effectiveness and potential systemic absorption. The original poster already uses 5% minoxidil and is seeking alternatives due to fears of finasteride's side effects.

      community European release of clascoterone

      in Research/Science  13 upvotes 2 months ago
      Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.